Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No CommentsThis website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the mentioned cookies and the acceptance of our Cookies policy.. ACEPTAR